SITC's Cancer Immunotherapy Guidelines program is a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure recommendations are unbiased, transparent, and balanced.
This guidelines addresses some of the most commonly reported irAEs that arise during treatment with ICIs, including gastrointestinal, musculoskeletal, and dermatologic toxicities, among other key considerations for oncologists treating their patients with these agents.
A companion guideline on the management of immune effector cell-related adverse events published on December 16, 2020 in the Journal for ImmunoTherapy of Cancer (JITC)
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events" originally published in Journal for Immunotherapy of Cancer (JITC) on June 25, 2021 and has since been updated.
SITC continuously evaluates the field for practice-changing data and new FDA approvals. The Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel guides the development of updates within this CPG. Updates appear in the SITC CPG Mobile App and as annotated text accompanying the original publication in JITC.
Highlights of Updated Content:
SITC is a proponent of collaboration and harmonization of efforts between like-minded organizations whenever possible. SITC wishes to thank the American Society for Transplantation and Cellular Therapy (ASTCT) for providing a representative to serve on SITC’s Immune Checkpoint Inhibitor-related Adverse Events Expert Panel to aid in the development of this clinical practice guideline.
Download the app for quick access to the immune checkpoint inhibitor-related adverse events CPG with interactive tools and companion education resources.
SITC is pleased to offer companion education resources in support of the published Immune Checkpoint Inhibitor-related Adverse Events CPG. These activities feature faculty comprised of the guideline expert panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios. The education available features one-hour webinars that take a deeper look at the guideline recommendations as well as mini-modules on a specific topic within the guideline content. Below is a list of the available educational resources for this CPG, available free and on-demand. Webinars:
For questions regarding SITC CPGs, please contact a member of the Scientific Publications Department at email@example.com.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org